Eli Lilly and Company, the maker of Axiron used in the treatment of low testosterone levels is one of the defendants in the over 6,000 centralized testosterone replacement therapy (TRT) lawsuits belonging to MDL No. 2545 in the U.S. District Court for the Northern District of Illinois under U.S. District Judge Matthew Kennelly. The company announced a settlement of all the Axiron cases filed against it in the MDL, a month before the start of its first bellwether trial, resulting in the cancellation of two upcoming trial dates in January and March by Judge Kennelly.
